Drug Trial Radar · NCT04240158
IW-6463 Safety Study in Healthy Elderly Subjects
Last checked: Nov 19, 2026Latest source record: Aug 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Jan 6, 2020
Primary completion
May 22, 2020
Study completion May 22, 2020
Sponsor
- Lead sponsor
- Tisento TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy male and female elderly participants.
Conditions
- Other
Interventions
IW-6463Drug
IW-6463 Tablet
Matching PlaceboDrug
Matching Placebo Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Cerebral Blood Flow (CBF) at Day 15Time frame: Baseline, 15 days
- Number of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 42 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Human Drug Research (CHDR)
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.